NEW YORK — Swiss diagnostics developer Calciscon said on Wednesday that it has raised $2.7 million in a Series A financing round led by Yellowstone Holding.
Calciscon said that it will use the money to accelerate the European rollout of its T50 Calcification Propensity blood test, a blood-based in vitro diagnostic that assesses the tendency for vascular calcification in patients with chronic kidney disease. The CE-marked test is currently available only in Switzerland.
Calciscon CEO Vincent Linder told GenomeWeb that the firm will also use the new funding to prepare for a US launch of T50 and is weighing two commercialization options: introducing it as a lab-developed test with a partner early this year and pursuing FDA clearance later, or seeking FDA clearance on its own for a potential launch in 2023 using funds from a planned Series B round.
In mid-2020, Calciscon raised $650,000 in pre-Series A funding.